search
Back to results

A Study of rhGAA in Patients With Late-Onset Pompe Disease

Primary Purpose

Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease

Status
Completed
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
Myozyme
Sponsored by
Genzyme, a Sanofi Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pompe Disease (Late-onset) focused on measuring Glycogen Storage Disease Type II, GSD-II, Pompe Disease

Eligibility Criteria

5 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related procedures; patient's signature required if patient understands informed consent patient must have a diagnosis of Pompe disease based on deficient endogenous GAA activity or GAA gene mutations patient must have demonstrable muscle weakness patient must be greater than or equal to five years of age and younger than eighteen years of age patient must be able to provide 3 reproducible FVC tests in sitting position during screening patient must perform muscle function testing patient must ambulate 10 meters (assistive devices permitted) patient and legal guardian must comply with the clinical protocol Exclusion Criteria: patient requires the use of invasive ventilatory support patient requires the use of noninvasive ventilatory support while awake and in an upright position patient has received enzyme replacement therapy with GAA from any source patient has used an investigational product within 30 days prior to study enrollment, or is currently enrolled in another clinical or observational study patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities Female patients pregnant, lactating or unwilling to practice birth control methods during study Male patients unwilling to use barrier contraceptives during study

Sites / Locations

  • Sophia Kinderziekenhuis, Erasmus MC

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

Outcomes

Primary Outcome Measures

safety and PK profile rhGAA
FVC
MMT
Effect of treatment on muscle function

Secondary Outcome Measures

Full Information

First Posted
November 8, 2005
Last Updated
February 4, 2014
Sponsor
Genzyme, a Sanofi Company
search

1. Study Identification

Unique Protocol Identification Number
NCT00250939
Brief Title
A Study of rhGAA in Patients With Late-Onset Pompe Disease
Official Title
Single-center, Open-label Study of Safety, Pharmacokinetics and Efficacy of rhGAA in Patients With Late-Onset Pompe Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
February 2005 (undefined)
Primary Completion Date
July 2006 (Actual)
Study Completion Date
November 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Genzyme, a Sanofi Company

4. Oversight

5. Study Description

Brief Summary
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, pharmacokinetics (PK) and efficacy of Myozyme treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2
Keywords
Glycogen Storage Disease Type II, GSD-II, Pompe Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
Myozyme
Other Intervention Name(s)
alglucosidase alfa
Intervention Description
20 mg/kg qow
Primary Outcome Measure Information:
Title
safety and PK profile rhGAA
Time Frame
74 weeks
Title
FVC
Time Frame
74 weeks
Title
MMT
Time Frame
74 weeks
Title
Effect of treatment on muscle function
Time Frame
74 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related procedures; patient's signature required if patient understands informed consent patient must have a diagnosis of Pompe disease based on deficient endogenous GAA activity or GAA gene mutations patient must have demonstrable muscle weakness patient must be greater than or equal to five years of age and younger than eighteen years of age patient must be able to provide 3 reproducible FVC tests in sitting position during screening patient must perform muscle function testing patient must ambulate 10 meters (assistive devices permitted) patient and legal guardian must comply with the clinical protocol Exclusion Criteria: patient requires the use of invasive ventilatory support patient requires the use of noninvasive ventilatory support while awake and in an upright position patient has received enzyme replacement therapy with GAA from any source patient has used an investigational product within 30 days prior to study enrollment, or is currently enrolled in another clinical or observational study patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities Female patients pregnant, lactating or unwilling to practice birth control methods during study Male patients unwilling to use barrier contraceptives during study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Genzyme, a Sanofi Company
Official's Role
Study Director
Facility Information:
Facility Name
Sophia Kinderziekenhuis, Erasmus MC
City
Rotterdam
ZIP/Postal Code
3015
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

A Study of rhGAA in Patients With Late-Onset Pompe Disease

We'll reach out to this number within 24 hrs